Generic Launch By Indian Drug Maker Blocked By New Patent Move
This article was originally published in PharmAsia News
India's Lupin may not be able to launch its generic version of the blood-pressure drug Altace (ramipril) in June as planned because of an action that could affect all Indian generics makers. Lupin had won its patent challenge against King Pharmaceuticals and Sanofi-Aventis, freeing it to market its generic when the patent expires June 7, but King has filed a citizen petition on a new patent. Other Indian drug makers have been assertive in trying to break patent protection in the United States, but the brand makers are fighting back. King's action requires an FDA review of the petition. (Click here for more
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.